Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer test. BeScreened improves access and affordability to CRC screening as a blood-draw instead of a fecal collection.
You must be a member to read this story.
Join our family of readers for as little as $5 per month and support local, unbiased journalism.
Current print subscribers can create a free account by clicking here
Otherwise, follow the link below to join.
To Our Valued Readers –
Visitors to our website will be limited to five stories per month unless they opt to subscribe. The five stories do not include our exclusive content written by our journalists.
For $6.99, less than 20 cents a day, digital subscribers will receive unlimited access to YourValley.net, including exclusive content from our newsroom and access to our Daily Independent e-edition.
Our commitment to balanced, fair reporting and local coverage provides insight and perspective not found anywhere else.
Your financial commitment will help to preserve the kind of honest journalism produced by our reporters and editors. We trust you agree that independent journalism is an essential component of our democracy. Please click here to subscribe.
Need to set up your free e-Newspaper all-access account? click here.
Non-subscribers
Click here to see your options for becoming a subscriber.
Register to comment
Click here create a free account for posting comments.
Note that free accounts do not include access to premium content on this site.
I am anchor
Cancer screening
Cancer test provides affordable early detection
Posted
Independent Newsmedia
Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer test.
BeScreened improves access and affordability to CRC screening as a blood-draw instead of a fecal collection.
The company is led by Jason McGrath, a colon cancer survivor.
Colorectal Cancer is the second deadliest and second most costly cancer in the United States. More than 150,000 American are newly diagnosed with CRC every year and greater than 50,000 Americans die from the disease annually.
Despite these alarming statistics, of the 131 million men and women in the US who are eligible each year for CRC screening, a staggering 45 million do not participate. BeScreened is a laboratory developed test that was developed for average risk men and women aged 45 and older who prefer blood-based testing to other screening modalities such as fecal-based tests and colonoscopy.
McGrath is an Iraq veteran who was diagnosed with stage 3 colon cancer at 41 years old. While undergoing 18 months of chemotherapy and three surgeries, he acquired Beacon Biomedical in 2022.
Beacon Biomedical developed the BeScreened-CRC test to drive improved compliance and early detection—which leads to survival rates of 90%, compared to just 14% if detected later.
"Too many lives are lost every year to colorectal cancer. The real tragedy is the majority of these deaths are preventable as they can be directly attributed to non-compliance with existing screening methods,” says Don Weber, Founder & CEO of Beacon Biomedical. “As a simple, easy to adopt, and highly accurate blood-based test for CRC screening, BeScreened was developed to address this very problem.”
BeScreened presents the trifecta in CRC screening. Individuals can purchase a test that is the preferred blood-based modality, is among the most accurate in the industry, and priced far more affordable than alternative screening options. The test is 94.6% accurate and cash priced at $349.
Tests are available now, across the country. Information can be found at www.BeScreened.com. Video, interviews, and images available immediately upon request.
